Blood Test Might Predict MS Relapse

Follow Drugslib on

By Dennis Thompson HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

TUESDAY, June 24, 2025 — A blood test might predict when multiple sclerosis patients are about to suffer a relapse in their symptoms, a new study says.

Blood levels of a protein called neurofilament light chain rise significantly in MS patients up to a year before they have a relapse, researchers reported Monday at a meeting of the European Academy of Neurology in Helsinki.

This sort of early detection can help doctors prepare for a relapse, ensuring timely treatment and potentially slowing the progression of MS, researchers said.

“Our findings significantly support the idea that serum neurofilament light chain (sNfL) has real potential for integration into routine monitoring of MS,” lead researcher Maria Martinez-Serrat, a doctoral student at the Medical University of Graz in Austria, said in a news release.

“Interpreted correctly, it could help clinicians anticipate disease activity, evaluate treatment response, and personalize care for patients at greater risk and ultimately enable earlier, more targeted interventions,” she said.

MS occurs when the immune system starts attacking the protective sheath that covers nerve cells, which is called myelin. This causes a wide-ranging and irreversible damage, impairing people’s ability to move, damaging their vision and causing problems with mood and memory.

People with early MS often will enter long periods of remission, with weeks or months of recovery between symptom flare-ups.

To see if these relapses could be predicted, researchers turned to neurofilament light chain — a protein that is released when nerve cells are damaged.

“Our aim was to explore how sNfL levels evolve over time and how they might serve as an early clinical warning sign of relapses in real-world settings,” Martinez-Serrat said.

For the study, researchers analyzed data from 162 MS patients tracked for around 10 years.

Results showed that sNfL levels could indeed predict an MS flare up, but only among those patients not currently suffering symptoms.

“When someone is already in relapse, sNfL levels are high due to ongoing nerve injury, which limits its predictive power,” Martinez-Serrat said. “But during remission, unexpected spikes in sNfL can flag hidden, emerging pathology — making it an effective early warning signal.”

However, the test could only predict MS flare-ups out to one year.

The test reflects current or recent nerve damage, “which makes it excellent for short-term risk assessment," Martinez-Serrat said. "But long-term prediction is confounded by treatment changes, lifestyle factors, or new inflammatory events.”

The protein’s levels also remained elevated for up to nine months after a person’s relapse, reflecting how long it can take for the body to recover, researchers said.

While sNfL shows promise as a test for MS patients, Martinez-Serrat cautioned against using it in isolation.

“MS is a multifaceted disease, and sNfL is one piece of the puzzle,” she said. “Future research may focus on combining it with other biomarkers … to build a more complete picture of disease trajectory.”

Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.

Sources

  • European Academy of Neurology, news release, June 23, 2025

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-06-25 00:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords